Moreover, 7,8-DHF treatment in a MPTP-mediated mouse model of PD blocked the striatal terminal loss by sustaining almost 54% of TH expression in the dorsolateral (DL) striatum and increasing the level of ganglion-10 (SCG10), TrkB phosphorylation, and ERK1/2 phosphorylation within the striatum and SN of MPTP-mediated C57BL/6J mouse model of PD [115]. This evidence concerns the gene MAPK3 and Parkinson disease.